Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.

PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages Read More

2024-03-25T09:03:49-07:00July 2nd, 2017|Adjuvant, Evidence, MammaPrint, MINDACT|
Read More

Risk Estimations and Treatment Decisions in Early Stage Breast Cancer: Agreement Among Oncologists and the Impact of the 70-Gene Signature

PUBLICATION: Eur J Cancer. 2014 Apr;50(6):1045-54. doi: 10.1016/j.ejca.2014.01.016. Epub 2014 Read More

2024-03-25T10:23:07-07:00April 1st, 2014|Adjuvant, Evidence, MammaPrint, RASTER|
Read More

Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer

PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Read More

2024-03-25T11:00:12-07:00May 2nd, 2010|Evidence, Healthcare Economics, MammaPrint, Other|
Read More

Daily Clinical Practice of Fresh Tumour Tissue Freezing and Gene Expression Profiling; Logistics Pilot Study Preceding the MINDACT Trial

PUBLICATION: Eur J Cancer. 2009 May;45(7):1201-1208. doi: 10.1016/j.ejca.2009.01.004. Epub 2009 Read More

2024-03-25T11:09:51-07:00May 1st, 2009|Evidence, MammaPrint, Other|
Read More


Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.

Go to Top